ScreenerHero

ANTX AN2 Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · an2therapeutics.com
4.850USD-4.34%Mkt Cap: 183.02M $P/E: —

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a on…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap183.02M USD
Enterprise Value112.94M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-35.17M USD
Revenue/Share—
Last Price4.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.34
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.42
EPS (TTM)-0.95
EPS (Forward)-0.80
52W Range
1.00062% of range7.190
52W High7.190 USD
52W Low1.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.29%
ROA-56.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.83M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9.84%
Net Debt-78.39M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio14.32
Quick Ratio14.09
Book Value/Sh2.09 USD
Cash/Share2.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+85.6%
Target Range9.000 USD – 9.000 USD
# Analysts2
Ownership
Shares Out.37.74M
Float22.29M
Insiders15.98%
Institutions76.88%
Short Interest
Short Ratio11.2d
Short % Float7.54%
Short % Out.6.35%
Shares Short2.40M
Short (prev mo.)2.22M
Technical
SMA 505.532 (-12.3%)
SMA 2003.798 (+27.7%)
Beta-0.98
S&P 52W Chg16.45%
Avg Vol (30d)267.89K
Avg Vol (10d)286.89K
Technical Indicators
RSI (14)39.4
MACD-0.0746
MACD Signal-0.0728
MACD Hist.-0.0019
BB Upper5.998 USD
BB Middle5.268 USD
BB Lower4.537 USD
BB Width27.74%
ATR (14)0.4007 USD
Vol Ratio (20d)1.34x